Is TCLIF or MRK a better dividend investment in 2026?

TCLIF currently yields 1176470.59% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: TCLIF offers higher current income.

What is the dividend yield difference between TCLIF and MRK?

TCLIF has a forward dividend yield of 1176470.59% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 1176467.83 percentage points.

Home › Compare › TCLIF vs MRK

TCLIF vs MRK: Dividend Comparison 2026

TCLIF yields 1176470.59% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 TCLIF wins by $2.4215110125896297e+37M in total portfolio value

INVESTMENT

TIME HORIZON10 years

TCLIF

● Live price

1176470.59%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2.4215110125896297e+37M

Annual income

$24,211,061,845,926,710,000,000,000,000,000,000,000,000,000.00

Full TCLIF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — TCLIF vs MRK

📍 TCLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	TCLIF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, TCLIF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

TCLIF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCLIF

Annual income on $10K today (after 15% tax)

$100,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$20,579,402,569,037,702,000,000,000,000,000,000,000,000,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, TCLIF beats the other by $20,579,402,569,037,702,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCLIF + MRK for your $10,000?

TCLIF: 50%MRK: 50%

100% MRK50/50100% TCLIF

Portfolio after 10yr

$1.2107555062948148e+37M

Annual income

$12,105,530,922,963,354,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.98%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TCLIF

No analyst data

Altman Z

-3.1

Piotroski

2/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCLIF buys

MRK buys

No recent congressional trades found for TCLIF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricTCLIFMRK

Forward yield	1176470.59% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$2.4215110125896297e+37M	$56.8K ✓
Annual income after 10y	$24,211,061,845,926,710,000,000,000,000,000,000,000,000,000.00 ✓	$9,798.13
Total dividends collected	$2.4214845246472507e+37M	$28.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: TCLIF vs MRK ($10,000, DRIP)

Year	TCLIF Portfolio	TCLIF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$117,657,759	$117,647,058.82	$11,206	$366.19	+$117.65M → TCLIF
2	$1,293,779,096,919	$1,293,653,203,117.42	$12,650	$502.35	+$1293779.08M → TCLIF
3	$13,295,934,568,100,894	$13,294,550,224,467,190.00	$14,407	$694.19	+$13295934568.09M → TCLIF
4	$127,701,793,229,051,900,000	$127,687,566,579,064,050,000.00	$16,585	$967.82	+$127701793229051.89M → TCLIF
5	$1,146,290,601,204,952,000,000,000	$1,146,153,960,286,197,000,000,000.00	$19,342	$1,363.89	+$1146290601204951936.00M → TCLIF
6	$9,616,395,428,956,886,000,000,000,000	$9,615,168,898,013,598,000,000,000,000.00	$22,913	$1,947.19	+$9.616395428956887e+21M → TCLIF
7	$75,396,293,251,698,080,000,000,000,000,000	$75,386,003,708,589,100,000,000,000,000,000.00	$27,662	$2,823.89	+$7.5396293251698075e+25M → TCLIF
8	$552,469,170,052,013,400,000,000,000,000,000,000	$552,388,496,018,234,040,000,000,000,000,000,000.00	$34,159	$4,173.35	+$5.524691700520134e+29M → TCLIF
9	$3,783,439,223,915,039,000,000,000,000,000,000,000,000	$3,782,848,081,903,083,000,000,000,000,000,000,000,000.00	$43,337	$6,308.80	+$3.783439223915039e+33M → TCLIF
10	$24,215,110,125,896,300,000,000,000,000,000,000,000,000,000	$24,211,061,845,926,710,000,000,000,000,000,000,000,000,000.00	$56,776	$9,798.13	+$2.4215110125896297e+37M → TCLIF

TCLIF vs MRK: Complete Analysis 2026

TCLIF — Stock

Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient's skin and optimizes the image quality. The company was founded in 2004 and is based in Malakoff, France.

Full TCLIF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this TCLIF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCLIF vs SCHD TCLIF vs JEPI TCLIF vs O TCLIF vs KO TCLIF vs MAIN TCLIF vs JNJ TCLIF vs ABBV TCLIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.